Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, March 9, 2022
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500)
Monday, March 7, 2022
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma
Friday, March 4, 2022
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab
Friday, February 25, 2022
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Tuesday, February 1, 2022
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
Monday, January 31, 2022
Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Friday, January 28, 2022
Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
Thursday, January 20, 2022
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
Wednesday, January 19, 2022
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: